Profit Margin Expansion: How Titan Biotech’s Operating Margin Doubled from 10% to 19% โ€” What Rising OPM Reveals About a Company’s Competitive Moat and Why Indian Investors Must Track This Metric

Profit Margin Expansion: How Titan Biotech’s Operating Margin Doubled from 10% to 19% โ€” What Rising OPM Reveals About a Company’s Competitive Moat and Why Indian Investors Must Track This Metric

๐Ÿ“… Published April 6, 2026 (Monday) โš ๏ธ THE F&O GAMBLING EPIDEMIC According to SEBI’s own study, 9 out of 10 individual traders in the equity Futures & Options segment incurred net losses. While millions of Indians gamble away their hard-earned

Contingent Liabilities Explained: The Hidden Time Bombs Lurking in Indian Company Balance Sheets That Most Investors Completely Ignore โ€” How Smart Value Investors Use This Critical Note to Avoid Catastrophic Losses

Contingent Liabilities Explained: The Hidden Time Bombs Lurking in Indian Company Balance Sheets That Most Investors Completely Ignore โ€” How Smart Value Investors Use This Critical Note to Avoid Catastrophic Losses

๐Ÿ“… Published April 06, 2026 (Monday) Why the Smartest Investors Read the Footnotes First Here’s a question most Indian retail investors never ask: “What liabilities does this company owe that don’t even appear on the balance sheet?” If you’ve ever

REITs and InvITs Explained: How Indian Investors Can Earn Rental Income and Infrastructure Yields Without Buying Property โ€” The Complete Guide to India’s Most Underused Wealth-Building Instruments

REITs and InvITs Explained: How Indian Investors Can Earn Rental Income and Infrastructure Yields Without Buying Property โ€” The Complete Guide to India’s Most Underused Wealth-Building Instruments

๐Ÿ“… Published April 04, 2026 (Saturday) The Problem: You Want Real Estate Income, But You Can’t Afford a โ‚น2 Crore Apartment Here’s a painful truth that every Indian investor knows: real estate has been the single largest wealth creator for

The Debt-Free Balance Sheet Superpower: Why Titan Biotech’s D/E Ratio of 0.02x Makes It a Fortress Stock โ€” How Zero-Debt Companies Outperform in Every Market Cycle and Why Indian Investors Must Prioritize Financial Strength Over Leverage

The Debt-Free Balance Sheet Superpower: Why Titan Biotech’s D/E Ratio of 0.02x Makes It a Fortress Stock โ€” How Zero-Debt Companies Outperform in Every Market Cycle and Why Indian Investors Must Prioritize Financial Strength Over Leverage

๐Ÿ“… Published April 4, 2026 (Saturday) ๐Ÿฐ Today’s Fundamental Analysis Lesson: The Debt-Free Balance Sheet Superpower SEBI’s landmark study revealed that 9 out of 10 individual traders in the equity Futures & Options segment incurred net losses. While millions of

Risk-Adjusted Returns: Why Sharpe Ratio and Sortino Ratio Are the Secret Weapons Smart Indian Investors Use to Measure True Portfolio Performance โ€” Stop Chasing Raw Returns and Start Measuring What Really Matters

Risk-Adjusted Returns: Why Sharpe Ratio and Sortino Ratio Are the Secret Weapons Smart Indian Investors Use to Measure True Portfolio Performance โ€” Stop Chasing Raw Returns and Start Measuring What Really Matters

๐Ÿ“… Published April 04, 2026 (Saturday) The Biggest Mistake Indian Investors Make: Judging Performance by Raw Returns Alone Imagine two mutual fund managers. Manager A delivers 25% returns in a year. Manager B delivers 20% returns. Which one is better?

Shameless Cloning: Mohnish Pabrai’s Genius Strategy of Copying the Best Investors โ€” Why Original Thinking Is Overrated and How Indian Investors Can Build Wealth by Legally Stealing Ideas from Superinvestors

Shameless Cloning: Mohnish Pabrai’s Genius Strategy of Copying the Best Investors โ€” Why Original Thinking Is Overrated and How Indian Investors Can Build Wealth by Legally Stealing Ideas from Superinvestors

Published April 4, 2026 (Saturday) Table of Contents Toggle The Most Counterintuitive Idea in Investing: Stop Trying to Be Original What Exactly Is Shameless Cloning? The Chain of Cloning: From Graham to Buffett to Pabrai The Academic Proof: Cloning Buffett